Tuesday, October 1, 2013

And the questions dance continua

1.Can infusion of purified IL-17 boost the anti-cancer property of IL-2?
2.Can infusion of IL4 (IL-10, TGF-beta) helps in treatment of autoimmune diseases
3.can elimination of Treg cells boost the effect of IL-2
4.Can TCR editing or "molecular mimicry" be used in cancer therapeutics.
5 What the associated biomarkers that could be in conjunction with HLA typing to predict response to therapy or cancer responsiveness to  autoimmune therapeutic intervention?
6.Can inhibitors of the  NOTCH pathways or the Wnt treat Pemphigus
7. what is the role of human opsonins in cancer therapy (surfactant A and D, Fibronectin, Vitronectin in lung cancer)

No comments: